CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

June 26, 2024 |

2 min read

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC) today announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company’s Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).

Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT

LA JOLLA, Calif. , June 26, 2024 /PRNewswire/ -- CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company’s Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).

Conference Call and Webcast Details
Stockholders and other interested parties may participate in the call by following the instructions below. A live webcast of the event can also be accessed in the “Upcoming Events” section of CalciMedica’s IR website at https://ir.calcimedica.com/. A replay of the webcast will be available following the completion of the event.

Participant Webcast Link: https://app.webinar.net/jDbvg4E9yPn

Click on the webcast link and complete the online registration form.
Upon registering, you will be connected to the online webcast.

Participant Dial-in Numbers: 1-800-836-8184 (US) and 1-646-357-8785 (international)

If prompted by the operator, ask to join the CalciMedica Phase 2b CARPO Topline Data Readout call.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica’s proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has completed a Phase 2b trial (called CARPO – NCT04681066) in AP with SIRS and a Phase 2b trial (called CARDEA – NCT04345614) in COVID pneumonia patients, continues to support the ongoing Phase 1/2 AIPT study (called CRSPA – NCT04195347), with data expected in 2025, and has initiated its Phase 2 study (called KOURAGE – NCT06374797) in AKI with associated AHRF with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.